Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline

(2022) Navneet Singh et al.   JOURNAL OF CLINICAL ONCOLOGY

LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial

(2022) K. Goto et al.   ANNALS OF ONCOLOGY

LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study

(2022) M.L. Johnson et al.   ANNALS OF ONCOLOGY

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline

(2022) Navneet Singh et al.   JOURNAL OF CLINICAL ONCOLOGY

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

(2021) Ferdinandos Skoulidis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer

(2021) Bob T. Li et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer

(2018) Katsuyuki Hotta et al.   Journal of Thoracic Oncology